Isturisa Helps Control Cortisol for 1.5+ Years in LINC-3 Study
Treatment with Isturisa (osilodrostat) for 1.5 years or longer kept urine cortisol levels close to normal in patients with Cushing’s disease, and this translated into fewer symptoms with no new side effects, a study has found. The findings come from an extension of LINC-3 (NCT02180217), a Phase…